Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ProTreg Treg02 in Kidney Transplant Recipients
2024-514398-23-00Phase 2Authorised
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Nov 2024
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of TREG02 in end-stage kidney disease (ESKD) and kidney allograft rejection, sponsored by Charité – Universitätsmedizin Berlin. Planned start Nov 2024; status: authorised.
02
Drugs
TREG02
03
Conditions
end-stage kidney disease (ESKD)kidney allograft rejection
Beyond the preview
Go deeper on 2024-514398-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514398-23-00.